High population immunity from prior infections and updated vaccines, combined with stable surveillance showing no rapidly dominant new strain, underpins traders' strong 86% consensus that no new COVID variant of concern will emerge before 2027. Omicron sublineages such as XFG and NB.1.8.1 currently drive most cases without meeting WHO or ECDC criteria for elevated transmissibility, severity, or immune escape. Recent monitoring of BA.3.2, which appeared in late 2025 and reached notable shares in parts of Europe, has not produced the explosive growth or clinical impact seen in earlier waves, thanks to lower fitness and broad existing protection. Ongoing genomic tracking and seasonal patterns further reduce the near-term likelihood of a concerning shift, though unexpected mutations could still alter trajectories before the deadline.